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Abstract
PEACH trial data was used to evaluate the relationship between subsequent STI and recurrent PID 
on infertility and chronic pelvic pain (CPP). Recurrent PID was associated with an almost two-
fold increased in infertility and more than four-fold increase in CPP. Subsequent STI was 
associated with CPP, but not infertility.
The Centers for Disease Control and Prevention (CDC) estimates that 800,000 women are 
affected by pelvic inflammatory disease (PID) each year in the United States.1 PID has the 
potential to result in significant reproductive health morbidity including tubal infertility, 
ectopic pregnancy, and chronic pelvic pain (CPP).2-4 Prior studies have demonstrated that 
women who have recurrent PID are at greater risk for reproductive morbidity than those 
women who are able to avoid subsequent disease.2 Our knowledge of the longitudinal 
outcomes for affected women who experience recurrent PID is primarily derived from 
seminal data published by Weström and colleagues using a Scandinavian cohort of 
inpatients diagnosed with PID between 1960 and 1984.2 Since that time, there have been 
shifts in the biological organisms associated with PID diagnoses and in behaviors.5-9 Prior 
studies have reported predominance of infection with Neisseria gonorrhoeae (GC) and 
Chlamydia trachomatis (CT), but newer work demonstrates that a third of PID cases are 
caused by these organisms.9 Also, in contrast to historical management of PID which was 
uniformly to hospitalize, management PID now relies on outpatient therapy and shorter 
hospital stays when utilized.10-12 Thus, an re-analysis of the impact of recurrent PID and 
subsequent sexually transmitted infections (STI) is warranted. In this study, we examine 
longitudinal secondary data from the PID Clinical Health and Evaluation (PEACH) study.
The PEACH) study is a multicenter randomized clinical trial designed to evaluate treatment 
strategies for PID. The methods for the PEACH study have been well reported in the 
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literature,13-15 but will be briefly reviewed here. Women aged 14-38 diagnosed with mild to 
moderate PID were recruited to participate in the trial between 1996-1999. In order to be 
included in the trial, participants had to have 1) pelvic discomfort for less than 30 days, 2) 
pelvic organ discomfort on bimanual examination, and 3) leukorrhea, mucopurulent 
cervicitis, and/ or known positivity for GC or CT via laboratory testing. Exclusion criteria 
included: 1) being identified as “at risk” for acute morbidity in the outpatient setting (e.g. 
pregnancy, inability to tolerate an outpatient regimen, tubo-ovarian abscess, potential 
surgical abdomen); pelvic pain ≥30 days; allergy to study drugs; antibiotic treatment within 
7 days of recruitment; gynecologic surgical procedure (including abortion) or delivery of an 
infant within the last 30 days; prior hysterectomy or salpingectomy; and homelessness.
One thousand five hundred fifteen women were approached about participation and after the 
exclusion of women who were ineligible or refused, 831 women were randomized to the 
inpatient and outpatient treatment arms. Inpatient antibiotic therapy consisted of 48 hours of 
intravenous cefoxitin (2g every 6 hours) and oral doxycycline (100 mg twice daily) while on 
an inpatient unit with oral doxycycline dosing to complete 14 days at discharge. Outpatient 
antibiotic therapy consisted of a single dose of cefoxitin 2g intramuscularly and probenecid 
1g orally, followed by 14 days of oral doxycycline 100mg twice daily. All patients were 
advised to rest, notify partners for treatment, and to abstain from sexual intercourse during 
treatment. At baseline, all participants completed a short interview (demographics, 
reproductive health history, sexual behavior) and had a gynecologic examination with 
specimen collection for GC (culture) and CT (polymerase chain reaction (Roche 
laboratories)), gram stain for bacterial vaginosis, and an endometrial biopsy for histological 
determination of endometritis. Participants were clinically re-evaluated a t 5- and 30-days. 
Each participant was then contacted quarterly for a telephone interview for 84-months 
during which interim diagnoses of subsequent STI and/or PID, pelvic pain, and infertility 
were assessed. This analysis was approved by the Johns Hopkins Institutional Review 
Board.
Measures
The primary outcomes of interest for this analysis were infertility and CPP at 84 months. 
Each of the primary outcome variables were measured as (yes, no) and dichotomously coded 
(1, 0). Infertility was defined when a sexually active woman with at least 12 months of 
follow-up did not conceive despite rare or no use of contraceptive method. Women were 
considered to have CPP if pelvic pain was reported during at least 2 consecutive follow-ups 
(i.e. minimum duration of 6 months). As previously reported,14 recurrent PID was similar by 
self-report and medical record review. Other variables of interest given the potential 
relationship to longitudinal outcomes included age, race, parity, prior GC infection, prior CT 
infection, pregnancy outcomes, and self-reported infertility from the baseline interview. 
Summary statistics were generated for each of the descriptive variables and the primary 
outcome variables using SAS (SAS, version 9.2, Cary, NC). Within the age group strata, we 
first conducted analyses (not shown) to examine whether there were differences by 
intervention status - inpatient versus outpatient therapy - from the parent study.13,14 In all 
bivariate analyses, chi-square and t-tests were used to evaluate differences for proportions 
and continuous variables, respectively. Multivariate logistic regression models were used to 
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evaluate the relationship between recurrent PID and/or recurrent STI and self-reported CPP 
and infertility. Models were adjusted for age, race, parity, prior PID, prior CT, and prior GC. 
In order to provide contrast to self-reported infertility findings, models predicting pregnancy 
and live birth were also performed and were adjusted for self-reported infertility at baseline. 
Finally, subgroup analyses were conducted for adolescents (≤19 years of age) to determine 
the potential impact of adolescence on the observed general outcomes in women.
At baseline, participants were primarily African American (75%), low income (77.5%) 
young women with regular access to healthcare (65%). (Table 1) All had clinical PID. At 
84-months of follow-up, 21.3% had recurrent PID, 19.0% were categorized as infertile, and 
42.7% reported CPP. Fifty-seven percent of women became pregnant and 42.0% had a live 
birth. There were no differences in pregnancies and live births based on recurrent PID. 
However, women who had recurrent PID were 1.8 times more likely to report infertility 
(AOR=1.8, 95% CI: 1.2; 2.8) and 4.2 times more likely to report CPP (AOR=4.2, 95% CI: 
2.8; 6.2) than women without a recurrent episode of PID; adjusting for age, race, parity, 
prior PID, GC, and CT. Women with subsequent lower genital tract infections (STI) were 
2.3 more likely to have CPP that those without STI (AOR=2.3, 95% CI: 1.2; 3.2), but not 
more likely to have infertility.
In the adolescent (≤19 years) sub-analysis, 71% of adolescents had a pregnancy, 51% had a 
live birth, 18 % were characterized as infertile, and 39% had CPP. There were no 
statistically significant differences in pregnancy (AOR: 1.1; 95% CI: 0.5:2.2), live birth 
(AOR: 0.9; 95% CI: 0.4; 1.7), adjusting for race, parity, prior PID, prior PID, GC, and CT, 
and self-reported infertility at baseline based on recurrent PID status. Adolescents with PID 
were also not significantly more likely to be categorized as having infertility (AOR: 1.9; 
95% CI: 0.8; 4.4), however were 5.0 times more likely to describe CPP (AOR: 5.0; 95% CI: 
2.3-10.6), controlling for race, parity, and prior PID, GC, and CT. (Table 2)
Women with recurrent episodes of PID are significantly more likely to report problems with 
infertility and CPP at 84 months. Our findings substantiate the established relationship 
between recurrent PID and adverse sequelae despite recent observations in the microbiology 
of PID and highlight CPP as a major longitudinal outcome for affected women. This work 
also draws attention to the notion that it is not just recurrent PID, but also recurrent lower 
genital tract infection (STI) that contributes to sequelae. It also supports to the concept of 
tertiary prevention, particularly since women affected by upper genital tract infection 
represent a smaller, but important and well- defined target group for intervention. 
Adolescents are also an important sub-target given the adverse risks to those so early in their 
reproductive trajectory. The strength of the study findings derive from use of the PEACH 
study sample which provides the most comprehensive longitudinal data available to date 
with urban American women affected by mild-moderate PID. It also provides excellent 
treatment efficacy data under the best possible conditions.
Our findings, however, must also be considered in light of several general limitations. 
Although the PEACH trial was designed to be generalizable to patients with clinically 
suspected PID diagnosed in urban settings, the sample may not be generalizeable to other 
dissimilar populations in the United States or those who would not participate in a trial. For 
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example, prior research among young women with PID suggests less than 25% of 
participants are using any form of contraception at the time of diagnosis,17 whereas more 
than 70% of women in the PEACH trial reported contraceptive use.18 Although the trial 
relied on clinical PID criteria for recruitment resulting in some patients without true PID, the 
design mimics current clinical practice. Finally, longitudinal outcome assessment relied on 
self-reported data from interviews conducted over the 84-month follow-up. While this poses 
a risk for reporting biases, medical record reviews substantiate recurrent PID diagnoses 
indicating the relative accuracy of self-reported medical histories by participants.
Young women with a history of PID are a clearly defined target group for public health 
intervention. Acute PID should prompt linkage of affected patients to tailored risk-reduction 
services to prevent the longitudinal sequelae associated with PID.
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Table 1
Selected Baseline Demographics






Insurance Status 43.8% (364)
Uninsured 13.8% (115)
Private 33.5% ( 278)
Public
Ever Pregnant 75.2% (625)
Prior history of PID 37.4% (311)
New Sexual Partner 9.3% (78)
Any Contraceptive use past 4 weeks 61.0% (508)
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Table 2
Logistic Regression Models: Recurrent PID, Subsequent STI, & Reproductive Health 






OR (95% CI) Adjusted OR (95% CI)*
Pregnancy** 95 (56.5) 356 (57.3) 1.0 (0.7 – 1.4) 1.0 (0.6 – 1.4)
Live Birth* 61 (36.3) 270 (43.5) 0.7 (0.5 – 1.1) 0.7 (0.5 – 1.0)
Infertility 44 (26.2) 104 (16.7) 1.8 (1.2 – 2.6) 1.8 (1.2 – 2.8)






OR (95% CI) Adjusted OR (95% CI)*
Pregnancy** 124 (63.6) 330 (55.4) 1.4 (1.0 – 2.0) 1.0 (0.7 – 1.5)
Live Birth* 91 (46.7) 239 (40.1) 1.3 (.09 – 1.8) 1.0 (0.7 – 1.4)
Infertility 41 (21.0) 104 (17.4) 1.3 (0.8 – 1.9) 1.4 (0.9 – 2.2)
Chronic pelvic pain 105 (53.8) 218 (37.7) 1.9 (1.4 – 2.7) 2.3 (1.6 – 3.2)





OR (95% CI) Adjusted OR (95% CI)*
Pregnancy** 34 (68.0) 108 (72.5) 0.8 (0.4 – 1.6) 1.1 (0.5 – 2.2)
Live Birth 22 (44.0) 80 (53.7) 0.7 (0.4 – 1.3) 0.9 (0.4 – 1.7)
Infertility 13 (26.0) 23 (15.4) 1.9 (0.9 – 4.2) 1.9 (0.8 – 4.4)





OR (95% CI) Adjusted OR (95% CI)*
Pregnancy** 47 (68.1) 97 (73.5) 0.8 (0.4 – 1.5) 0.9 (0.5 – 1.8)
Live Birth 32 (46.4) 71 (53.8) 0.7 (0.4 – 1.3) 0.9 (0.5 – 1.6)
Infertility 17 (24.6) 18 (13.6) 2.1 (1.0 – 4.3) 1.9 (0.9 – 4.2)
Chronic pelvic pain 36 (52.2) 42 (32.6) 2.3 (1.2 – 4.1) 2.3 (1.2 – 4.5)
*
Adjusted for age, race, parity, prior PID, prior GC and prior CT. Models predicting pregnancy and live birth are additionally adjusted for self-
reported infertility at baseline.
**
Models predicting pregnancy and live birth were also performed and were adjusted for self-reported infertility at baseline
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